{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:57:34Z","timestamp":1770227854479,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007856","name":"Baylor College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcyt.2024.08.004","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T21:49:55Z","timestamp":1723240195000},"page":"7-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["CD19-chimeric antigen receptor-invariant natural killer T cells transactivate NK cells and reduce alloreactivity"],"prefix":"10.1016","volume":"27","author":[{"given":"Anton","family":"Wesle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Moraes Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebekka","family":"Schairer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7115-3560","authenticated-orcid":false,"given":"Hildegard","family":"Keppeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulya","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia","family":"Radszuweit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2672-431X","authenticated-orcid":false,"given":"Dominik","family":"Schneidawind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina","family":"Schneidawind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.08.004_bib0001","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1084\/jem.20011786","article-title":"Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining","volume":"195","author":"Gumperz","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02647.x","article-title":"Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11","volume":"122","author":"Montoya","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0003","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4049\/jimmunol.162.1.161","article-title":"Diverse TCRs recognize murine CD1","volume":"162","author":"Behar","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0004","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2003-04-1155","article-title":"Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity","volume":"103","author":"Nieda","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0005","doi-asserted-by":"crossref","first-page":"e14374","DOI":"10.1371\/journal.pone.0014374","article-title":"\u0391-galactosylceramide analogs with weak agonist activity for human iNKT cells define new candidate anti-inflammatory agents","volume":"5","author":"Bricard","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0006","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.4049\/jimmunol.163.9.4647","article-title":"Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells","volume":"163","author":"Carnaud","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0007","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nri3369","article-title":"Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions","volume":"13","author":"Brennan","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0008","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1056\/NEJM199103073241005","article-title":"Graft-versus-host disease","volume":"324","author":"Ferrara","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0009","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1182\/blood-2014-05-576017","article-title":"CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells","volume":"124","author":"Schneidawind","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0010","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood-2014-11-612762","article-title":"Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality","volume":"125","author":"Schneidawind","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0011","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2016-11-752444","article-title":"Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells","volume":"129","author":"Du","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0012","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2012-01-404673","article-title":"Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival","volume":"120","author":"Rubio","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0013","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1182\/blood-2011-11-389304","article-title":"Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Chaidos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0014","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2015-12-688739","article-title":"Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival","volume":"127","author":"Malard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0015","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0016","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0017","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0018","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0021","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0022","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1158\/1078-0432.CCR-21-1329","article-title":"Allogeneic CAR invariant natural killer T cells exert potent antitumor effects through host CD8 T-cell cross-priming","volume":"27","author":"Simonetta","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0023","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1189\/jlb.0611308","article-title":"Natural killer cell-produced IFN-\u03b3 and TNF-\u03b1 induce target cell cytolysis through up-regulation of ICAM-1","volume":"91","author":"Wang","year":"2012","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0024","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/s10165-005-0426-6","article-title":"Granzyme B and natural killer (NK) cell death","volume":"15","author":"Ida","year":"2005","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0025","doi-asserted-by":"crossref","first-page":"10082","DOI":"10.1038\/s41598-023-36468-8","article-title":"The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant Natural Killer T cell function","volume":"13","author":"Balasko","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2024.08.004_bib0026","doi-asserted-by":"crossref","first-page":"8305","DOI":"10.3390\/ijms21218305","article-title":"Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies?","volume":"21","author":"Hosseinkhani","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924008247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924008247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:09:14Z","timestamp":1762546154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924008247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1465324924008247"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.08.004","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD19-chimeric antigen receptor-invariant natural killer T cells transactivate NK cells and reduce alloreactivity","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}